CLDN18.2 POSITIVE
Clinical trials for CLDN18.2 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CLDN18.2 POSITIVE trials appear
Sign up with your email to follow new studies for CLDN18.2 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat cancers: drug combo targets specific tumor marker
Disease control Recruiting nowThis study tests a new drug called IBI343 combined with other treatments for people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination is safe and shrinks tumors. About 389 adults …
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding the experimental drug IBI343 to standard chemotherapy and immunotherapy before and after surgery can improve outcomes for people with a certain type of advanced stomach or gastroesophageal junction cancer. About 90 adults whose tumors have a specif…
Matched conditions: CLDN18.2 POSITIVE
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC